Clinically, everolimus and mTOR inhibitor plus a PI3K inhibitor (BKM120), Akt inhibitor (MK-2206), and mTOR/PI3K inhibitor (BEZ235) significantly increase immune cytotoxic activity, especially in treatment of advanced HCC via everolimus, in which 40–73% patients quickly catch the disease stable state in a short-time study (146, 147). This evidence concerns the gene MTOR and hepatocellular carcinoma.